Method of inhibiting conditions associated with bradykinin

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/445 (2006.01) A61K 31/40 (2006.01) A61K 31/4025 (2006.01) A61K 31/4535 (2006.01) A61K 31/55 (2006.01)

Patent

CA 2203914

A method of inhibiting a physiological condition associated with an excess of bradykinin comprising administering to a human in need thereof an effective amount of a compound having formula (I) wherein R1 and R3 are independently hydrogen, -CH3, (a) or (b), wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneimino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

Procédé permettant de traiter des troubles physiologiques dus à un excédent de bradykinine. Il consiste à administrer à un patient une quantité efficace d'un composé de formule (I) où R?1¿ et R?3¿ représentent indépendemment hydrogène, -CH¿3?, (a) ou (b), où Ar représente phényle éventuellement substitué; R?2¿ est choisi dans le groupe consistant en pyrrolidine, hexaméthylèneimino et pipéridino. L'invention concerne ce composé ou un de ses sels de solvate pharmacologiquement acceptables.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Method of inhibiting conditions associated with bradykinin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of inhibiting conditions associated with bradykinin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting conditions associated with bradykinin will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1449700

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.